F2R and systemic sclerosis: Blockade of the endothelial PAR-1 or c-FOS/AP-1 silencing or SSc therapy by anti-IL-6 receptor antibody tocilizumab provides further evidence of involving Abs against the PAR-1 in the pathomechanism of SSc (6, 70).